Episurf Medical (STO:EPISB) (NASDAQ:EPISB), a provider of minimally invasive and individualised treatment alternatives for people with painful joint injuries, revealed on Friday that it expects to receive CE marking for the Episealer Talus ankle implant very soon.
The review process for obtaining the CE mark for Episealer Talus has now been concluded and the final formal process for issuing the CE certificate is expected to be completed within the next two weeks.
The implant is intended for osteochondral lesions of the talar dome of the ankle joint. It is based on the same technology platform as the company's Episealer knee devices, with an individualised design based on medical imaging and 3D modulation.
Episurf Medical has also applied for CE marking for an individualised osteotomy guide that is intended to help surgeons to find the correct position and depth of sawing when performing a medial malleolar osteotomy.
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Elute partners Spartan Medical
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Abbott's Navitor TAVI system granted CE Mark for expanded indication
PharmaResearch names VIVACY as European distribution partner for Rejuran
Airiver medical receives FDA approval for central airway stenosis trial